Tomohiro Yazawa1, Kimihiro Shimizu1, Kyoichi Kaira2, Toshiteru Nagashima1, Yoichi Ohtaki1, Jun Atsumi1, Kai Obayashi1, Shushi Nagamori3, Yoshikatsu Kanai3, Tetsunari Oyama4, Izumi Takeyoshi1. 1. Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine Maebashi, Gunma, Japan. 2. Department of Oncology Clinical Development, Gunma University Graduate School of Medicine Maebashi, Gunma, Japan. 3. Division of Bio-System Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University Osaka, Japan. 4. Department of Diagnostic Pathology, Gunma University Graduate School of Medicine Maebashi, Gunma, Japan.
Abstract
BACKGROUND: L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) have been associated with tumor growth and progression. However, the clinical significance of LAT1 and ASCT2 coexpression in the prognosis of patients with lung adenocarcinoma remains unclear. METHODS: In total, 222 patients with surgically resected lung adenocarcinoma were investigated retrospectively. Tumor sections were stained immunohistochemically for LAT1, ASCT2, CD98, phosphorylated mammalian target-of-rapamycin (p-mTOR), and Ki-67, and microvessel density (MVD) was determined by staining for CD34. Epidermal growth factor receptor (EGFR) mutation status was also examined. RESULTS: LAT1 and ASCT2 were positively expressed in 22% and 40% of cases, respectively. Coexpression of LAT1 and ASCT2 was observed in 12% of cases and was associated significantly with disease stage, lymphatic permeation, vascular invasion, CD98, Ki-67, and p-mTOR. Only LAT1 and ASCT2 coexpression indicated a poor prognosis for lung adenocarcinoma. Furthermore, this characteristic was recognized in early-stage patients, especially those who had wild-type, rather than mutated, EGFR. Multivariate analysis confirmed that the coexpression of LAT1 and ASCT2 was an independent factor for predicting poor outcome. CONCLUSIONS: LAT1 and ASCT2 coexpression is an independent prognostic factor for patients with lung adenocarcinoma, especially during the early stages, expressing wild-type EGFR.
BACKGROUND:L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) have been associated with tumor growth and progression. However, the clinical significance of LAT1 and ASCT2 coexpression in the prognosis of patients with lung adenocarcinoma remains unclear. METHODS: In total, 222 patients with surgically resected lung adenocarcinoma were investigated retrospectively. Tumor sections were stained immunohistochemically for LAT1, ASCT2, CD98, phosphorylated mammalian target-of-rapamycin (p-mTOR), and Ki-67, and microvessel density (MVD) was determined by staining for CD34. Epidermal growth factor receptor (EGFR) mutation status was also examined. RESULTS:LAT1 and ASCT2 were positively expressed in 22% and 40% of cases, respectively. Coexpression of LAT1 and ASCT2 was observed in 12% of cases and was associated significantly with disease stage, lymphatic permeation, vascular invasion, CD98, Ki-67, and p-mTOR. Only LAT1 and ASCT2 coexpression indicated a poor prognosis for lung adenocarcinoma. Furthermore, this characteristic was recognized in early-stage patients, especially those who had wild-type, rather than mutated, EGFR. Multivariate analysis confirmed that the coexpression of LAT1 and ASCT2 was an independent factor for predicting poor outcome. CONCLUSIONS:LAT1 and ASCT2 coexpression is an independent prognostic factor for patients with lung adenocarcinoma, especially during the early stages, expressing wild-type EGFR.
Authors: Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: K Shimizu; K Kaira; Y Tomizawa; N Sunaga; O Kawashima; N Oriuchi; H Tominaga; S Nagamori; Y Kanai; M Yamada; T Oyama; I Takeyoshi Journal: Br J Cancer Date: 2014-03-06 Impact factor: 7.640
Authors: Evan Augustyn; Karissa Finke; Arik A Zur; Logan Hansen; Nathan Heeren; Huan-Chieh Chien; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas Journal: Bioorg Med Chem Lett Date: 2016-04-11 Impact factor: 2.823
Authors: Rachel-Ann A Garibsingh; Nicholas J Otte; Elias Ndaru; Claire Colas; Christof Grewer; Jeff Holst; Avner Schlessinger Journal: Front Chem Date: 2018-07-24 Impact factor: 5.221
Authors: Tineke W H Meijer; Monika G Looijen-Salamon; Jasper Lok; Michel van den Heuvel; Bastiaan Tops; Johannes H A M Kaanders; Paul N Span; Johan Bussink Journal: Thorac Cancer Date: 2019-10-30 Impact factor: 3.500